Metolazone NDC 72888-053

NDC codes

FDA NDC Directory

Product NDC (as listed)72888-053Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72888-0053Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72888-053-01	72888005301	100 TABLET in 1 BOTTLE (72888-053-01)Marketed from Aug 20, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Metolazone
Generic name (nonproprietary): metolazone
Active ingredients: Metolazone — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Advagen Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215184
Marketing start: Aug 20, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Increased Diuresis (Physiologic effect)
Identifiers: Product ID 72888-053_486ae202-9be8-35ef-e063-6294a90adb8aSPL ID 486ae202-9be8-35ef-e063-6294a90adb8aSPL set ID 6a9c8415-e389-7a9a-73de-532cf3f57ac5RxCUI 197978, 197979, 311671UNII TZ7V40X7VXUPC 0372888053011, 0372888054018, 0372888052014
Pharmacologic class: Thiazide-like Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472888005301 followed by a unit qualifier and the quantity

Package 72888-0053-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 15, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Metolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for metolazone tablets, USP, in the treatment of hypert…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215184

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215184
Product	Strength	Form · route	Labeler	Product NDC
Metolazone	Metolazone 2.5 mg/1	TabletOral	A-S Medication Solutions	50090-6972
Metolazone	Metolazone 2.5 mg/1	TabletOral	Advagen Pharma Limited	72888-052
Metolazone	Metolazone 10 mg/1	TabletOral	Advagen Pharma Limited	72888-054